Feature | November 01, 2013

Trial Examines Benefits of iFR vs. FFR to Determine Severity of Coronary Artery Disease

Results of the ADVISE II Trial Presented at TCT 2013

cath lab clinical trial study fraction flow reserve FFR

November 1, 2013 — A study supports the use of instantaneous wave-free ratio (iFR) to simplify assessment and determine the severity of coronary artery disease (CAD). ADVISE II findings were presented at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013).
 
ADVISE II enrolled 797 patients in a prospective, observational, non-randomized double blind global multi-center registry study with an adaptive design. The diagnostic performance of iFR was analyzed both as a dichotomous index and as part of a hybrid iFR/FFR strategy. iFR was used according to specific cutoffs (iFR zone, ? 0.85 and ? 0.94) with high positive and high negative predictive value for the detection of hemodynamically severe stenosis. FFR use was limited to the “adenosine zone” for iFR values between 0.86 and 0.93. The primary endpoint was the percentage of stenosis properly classified in terms of hemodynamic severity (FFR value ? 0.8). 
 
The final study population consisted of 690 stenoses and of these, 31 percent had an associated iFR value in the adenosine zone (0.86-0.93) while 69 percent had associated iFR values in the iFR zone. Within the iFR zone, the percentage of stenosis properly classified in terms of hemodynamic severity was 91.6 percent. Overall the hybrid iFR/FFR approach correctly classified 94.2 percent of coronary stenoses, without the need for adenosine administration in 65.1 percent of patients.
 
“The results of the ADVISE II study support the use of iFR to simplify physiological guidance of percutaneous coronary intervention,” said Javier Escaned, M.D, Ph.D., interventional cardiologist, Hospital Clinico San Carlos, Madrid, Spain, and lead investigator of the study.
 
“The promising results demonstrate the potential of boosting the benefits of ischemia-driven revascularization to a larger proportion of patients with coronary artery disease.”
 
For more information: www.crf.org

Related Content

News | Cardiovascular Clinical Studies

March 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...

Home March 27, 2023
Home
News | Cardiovascular Clinical Studies

March 24, 2023 — Vaxxinity, Inc., a Cape Canaveral, FL-based company pioneering the development of a new class of ...

Home March 24, 2023
Home
News | Cardiovascular Clinical Studies

March 22, 2023 — Ancora Heart, Inc., a privately-held Santa Clara, CA-based company developing a completely ...

Home March 22, 2023
Home
News | Cardiovascular Clinical Studies

March 21, 2023 — The first platform to combine real-world cardiology data from millions of people in multiple European ...

Home March 21, 2023
Home
News | Cardiovascular Clinical Studies

March 13, 2023 — BioCardia, Inc., developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2023
Home
News | Cardiovascular Clinical Studies

March 8, 2023 — A unique community-based partnership, the African American Heart Study, will be conducted to measure the ...

Home March 08, 2023
Home
News | Cardiovascular Clinical Studies

March 6, 2023 — A multifaceted intervention to improve prescribing practices increased the likelihood that patients with ...

Home March 06, 2023
Home
News | Cardiovascular Clinical Studies

March 5, 2023 — Providing medications for chronic diseases—for example, cholesterol-lowering, blood pressure and ...

Home March 05, 2023
Home
News | Cardiovascular Clinical Studies

March 5, 2023 — The number of deaths and disabling strokes among patients at low surgical risk who were treated with ...

Home March 05, 2023
Home
News | Cardiovascular Clinical Studies

March 5, 2023 — In the largest randomized trial conducted to compare minimally invasive and conventional cardiac ...

Home March 05, 2023
Home
Subscribe Now